Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation

Trial Profile

Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Angiotensin-1-7 (Primary)
  • Indications Neutropenia; Thrombocytopenia
  • Focus Adverse reactions
  • Sponsors US Biotest Inc
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 10 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
    • 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top